CX Institutional Has $10.30 Million Position in Johnson & Johnson (NYSE:JNJ)

CX Institutional boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,134 shares of the company’s stock after acquiring an additional 3,821 shares during the quarter. CX Institutional’s holdings in Johnson & Johnson were worth $10,304,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Tallon Kerry Patrick acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $290,000. Capital & Planning LLC boosted its holdings in Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock valued at $221,000 after acquiring an additional 183 shares during the last quarter. Brighton Jones LLC boosted its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Union Bancaire Privee UBP SA bought a new position in Johnson & Johnson in the fourth quarter valued at about $85,886,000. Finally, Prairie Wealth Advisors Inc. boosted its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Prairie Wealth Advisors Inc. now owns 3,061 shares of the company’s stock valued at $443,000 after acquiring an additional 84 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Bank of America decreased their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Trading Up 0.8%

NYSE JNJ opened at $156.45 on Wednesday. The firm has a market cap of $376.43 billion, a P/E ratio of 23.53, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock’s 50-day moving average is $153.52 and its 200-day moving average is $153.69. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.32%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.